Has Ron Landmann, MD received payments from drug or device companies?

Yes. Drug and device makers reported $224,301 in general payments to Ron Landmann, MD across 252 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ron Landmann, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ron Landmann, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ron Landmann, MD

Colon & Rectal Surgery · Jacksonville, FLNPI 1407013592

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $191,333 of the $224,301 with a category attached, or 85.3%. Johnson & Johnson accounts for 81.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $72,191 and has fallen 90.9% since, to $6,586 in 2025. Among colon & rectal surgery clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$224,301in general payments, 2019–2025

Across 252 payments — averaging $890.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$182K
Medical Device Business Services, Inc.$33K
Davol Inc.$4K
Intuitive Surgical$3K
Ethicon Endo-surgery Inc.$1K
Ambu Inc.$1K
plus $536 from 5 others

$7,761in research payments, 2019–2025

Across 2 payments — averaging $3880.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$8K

What the payments were for

Consulting fees$191,33385%
Speaking & faculty fees$3,5002%
Travel & lodging$21,42110%
Food & beverage$7,2973%
Education$7500%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	169	$182,248
Medical Device Business Services, Inc.	36	$32,870
Davol Inc.	5	$3,758
Intuitive Surgical	23	$2,631
Ethicon Endo-surgery Inc.	5	$1,152
Ambu Inc.	6	$1,105
Medtronic	4	$170
On Target Laboratories, Inc	1	$150
Boston Scientific	1	$143
Reddress USA, Inc.	1	$45
TELA Bio, Inc.	1	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ETHICON ENDO-SURGERY Curved Intraluminal Stapler$19,799
ECHELON FLEX Stapler$19,696
ECHELON ENDOPATH Stapler$15,151
Echelon Circular$9,907
Echelon Flex$9,666
ECHELON ENDOPATH$4,610
N/A$4,522
Da Vinci Surgical System$2,055
Echelon Powered Circular$969
Enseal$619
Harmonic$498
Megadyne$154
SURGIFLO Hemostatic Matrix$154
Cytalux$150
Monarch Platform$133
Echelon Endopath Staple Line Reinforcement$128

How this compares

$224,301 in reported general payments places this provider in the 90th percentile of 157 colon & rectal surgery providers in Florida.

See all colon & rectal surgery providers in Florida →

Medicare billing

Part B allowed, 2024

$103,889

Medicare patients

155

Services billed

475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ErythromycinErythromycin Base	40	$1,604
Neomycin Sulfate	42	$207

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Jacksonville

Luca StocchiJacksonville$14K
Neil GibsonJacksonville$11K
Mark SolimanAltamonte Springs$872K
Eduardo Parra DavilaWest Palm Beach$577K
Matthew AlbertAltamonte Springs$514K
Avraham BelizonBoca Raton$482K
Rahila EssaniCelebration$379K
Henry LujanMiami$378K
Steven WexnerWeston$333K
Allen ChudzinskiTampa$252K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →